Chimerix Inc (NASDAQ: CMRX) stock fell -3.02% on Friday to $0.97 against a previous-day closing price of $1.00. With 0.79 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.54 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.0200 whereas the lowest price it dropped to was $0.9500. The 52-week range on CMRX shows that it touched its highest point at $2.39 and its lowest point at $0.88 during that stretch. It currently has a 1-year price target of $7.00. Beta for the stock currently stands at 1.13.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CMRX was up-trending over the past week, with a rise of 3.17%, but this was down by -4.92% over a month. Three-month performance dropped to -3.02% while six-month performance fell -19.85%. The stock lost -55.92% in the past year, while it has lost -47.86% so far this year. A look at the trailing 12-month EPS for CMRX yields -0.96 with Next year EPS estimates of -0.82. For the next quarter, that number is -0.24. This implies an EPS growth rate of -149.26% for this year and 13.75% for next year.
Float and Shares Shorts:
At present, 88.05 million CMRX shares are outstanding with a float of 79.36 million shares on hand for trading. On Oct 30, 2023, short shares totaled 1.65 million, which was 1.85% higher than short shares on Sep 28, 2023. In addition to Mr. Michael T. Andriole M.B.A. as the firm’s CEO, President & Director, Dr. Allen S. Melemed M.B.A., M.D. serves as its Chief Medical Officer.
Through their ownership of 61.89% of CMRX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 9.32% of CMRX, in contrast to 36.76% held by mutual funds. Shares owned by individuals account for 19.55%. As the largest shareholder in CMRX with 7.34% of the stake, RA Capital Management LP holds 6,501,624 shares worth 6,501,624. A second-largest stockholder of CMRX, Monaco Asset Management SAM, holds 4,377,674 shares, controlling over 4.94% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in CMRX, holding 4,320,848 shares or 4.88% stake. With a 3.28% stake in CMRX, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 2,904,360 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.48% of CMRX stock, is the second-largest Mutual Fund holder. It holds 1,308,906 shares valued at 1.23 million. Pictet Asset holds 0.91% of the stake in CMRX, owning 805,138 shares worth 0.76 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CMRX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With CMRX analysts setting a high price target of $11.00 and a low target of $5.00, the average target price over the next 12 months is $7.00. Based on these targets, CMRX could surge 1034.02% to reach the target high and rise by 415.46% to reach the target low. Reaching the average price target will result in a growth of 621.65% from current levels.
Summary of Insider Activity:
Insiders traded CMRX stock several times over the past three months with 1 Buys and 1 Sells. In these transactions, 20,000 shares were bought while 3,610 shares were sold. The number of buy transactions has increased to 12 while that of sell transactions has risen to 2 over the past year. The total number of shares bought during that period was 395,215 while 6,840 shares were sold.